Recorded Events

POST AIDS 2022 Webinar

POST AIDS 2022 Webinar

Expert Panel Discussion of 2022 AIDS ViiV-Sponsored Data

POST AIDS 2022 Webinar

Expert Panel Discussion of 2022 AIDS ViiV-Sponsored Data
Utilizing and Applying Findings from Observational Studies in AIDS Research

Utilizing and Applying Findings from Observational Studies in AIDS Research

Shelly Dhir, PharmD Sr. Director, Portfolio Medical Lead
Dr. Rick Elion, MD Director of Clinical Research, Washington Health Institute and Clinical Professor of Medicine George Washington University School of Medicine

Utilizing and Applying Findings from Observational Studies in AIDS Research

Shelly Dhir, PharmD Sr. Director, Portfolio Medical Lead
Dr. Rick Elion, MD Director of Clinical Research, Washington Health Institute and Clinical Professor of Medicine George Washington University School of Medicine
Using Fewer HIV Treatments When Treating HIV Long Term

Using Fewer HIV Treatments When Treating HIV Long Term

Andrew Zolopa, MD VP, Head, North American Medical Affairs ViiV Healthcare
Dr. Babafemi Taiwo, MD, MBBS Gene Stollerman Professor of Medicine and Chief of the Division of Infectious Diseases Northwestern University

Using Fewer HIV Treatments When Treating HIV Long Term

Andrew Zolopa, MD VP, Head, North American Medical Affairs ViiV Healthcare
Dr. Babafemi Taiwo, MD, MBBS Gene Stollerman Professor of Medicine and Chief of the Division of Infectious Diseases Northwestern University
Discussing CABENUVA Data at AIDS 2022

Discussing CABENUVA Data at AIDS 2022

Bruce Gilliam, MD, FACP Sr. Medical Director, North American Medical Affairs
Dr. Moti Ramgopal, MD, FIDSA, FACP Associate Professor of Medicine Medical Director Midway Reasearch Center and Found of Midway Specialty Care Centers

Discussing CABENUVA Data at AIDS 2022

Bruce Gilliam, MD, FACP Sr. Medical Director, North American Medical Affairs
Dr. Moti Ramgopal, MD, FIDSA, FACP Associate Professor of Medicine Medical Director Midway Reasearch Center and Found of Midway Specialty Care Centers
Discussing the BRIGHTE Study at AIDS 2022

Discussing the BRIGHTE Study at AIDS 2022

Bruce Gilliam, MD, FACP Sr. Medical Director, North American Medical Affairs
Dr. Moti Ramgopal, MD, FIDSA, FACP Associate Professor of Medicine Medical Director Midway Reasearch Center and Found of Midway Specialty Care Centers

Discussing the BRIGHTE Study at AIDS 2022

Bruce Gilliam, MD, FACP Sr. Medical Director, North American Medical Affairs
Dr. Moti Ramgopal, MD, FIDSA, FACP Associate Professor of Medicine Medical Director Midway Reasearch Center and Found of Midway Specialty Care Centers
Caring for Patients with Multidrug Resistant (MDR) HIV - A Focus on Patient Identification and ARV Management with Q&A

Caring for Patients with Multidrug Resistant (MDR) HIV - A Focus on Patient Identification and ARV Management with Q&A

Alftan Dyson, PharmD | Bruce Gilliam, MD | Elizabeth Race, MD, MPH| Moti Ramgopal, MD, FACP, FIDSA

Caring for Patients with Multidrug Resistant (MDR) HIV - A Focus on Patient Identification and ARV Management with Q&A

Alftan Dyson, PharmD | Bruce Gilliam, MD | Elizabeth Race, MD, MPH| Moti Ramgopal, MD, FACP, FIDSA
Post Fall Conference 2021 Webinar

Post Fall Conference 2021 Webinar

Dr. Andrew Zolopa, ViiV Medical Experts

Post Fall Conference 2021 Webinar

Dr. Andrew Zolopa, ViiV Medical Experts
Post-IAS 2021 Webinar

Post-IAS 2021 Webinar

Dr. Andrew Zolopa, ViiV Medical Experts

Post-IAS 2021 Webinar

Dr. Andrew Zolopa, ViiV Medical Experts
The ABCs of CAB: Incorporating Long-Acting Cabenuva into Clinical Practice

The ABCs of CAB: Incorporating Long-Acting Cabenuva into Clinical Practice

Paula Teichner, PharmD, AAHIVP, Regional Medical Lead

The ABCs of CAB: Incorporating Long-Acting Cabenuva into Clinical Practice

Paula Teichner, PharmD, AAHIVP, Regional Medical Lead
Post-CROI 2021 Webinar

Post-CROI 2021 Webinar

Andrew Zolopa, MD, VP, Head, North America Medical Affairs

Post-CROI 2021 Webinar

Andrew Zolopa, MD, VP, Head, North America Medical Affairs
STAT 24 Week: Feasibility, Efficacy and Safety

STAT 24 Week: Feasibility, Efficacy and Safety

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

STAT 24 Week: Feasibility, Efficacy and Safety

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
TANGO 96 Week: Efficacy and Safety

TANGO 96 Week: Efficacy and Safety

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

TANGO 96 Week: Efficacy and Safety

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
GEMINI 144 Week: Efficacy and Safety

GEMINI 144 Week: Efficacy and Safety

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

GEMINI 144 Week: Efficacy and Safety

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir
GEMINI 48 Week: Adherence Analysis

GEMINI 48 Week: Adherence Analysis

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

GEMINI 48 Week: Adherence Analysis

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir